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The current standard of care for locally advanced non-small cell lung cancer (NSCLC)
includes radiation, chemotherapy, and surgery in certain individualized cases. In unresectable NSCLC, chemoradiation has been the standard of care for the past three
decades. Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and national clinical trials. Though initial
studies showed a benefit to dose escalation, phase III studies examining dose escalation
using standard fractionation or hyperfractionation have failed to show a benefit. Over the
last 17 years, stereotactic body radiation therapy (SBRT) has shown a high degree of
safety and local control for stage I lung cancers and other localized malignancies. More
recently, phase I/II studies using SBRT for dose escalation after conventional chemoradiation in locally advanced NSCLC have been promising with good apparent safety.
Immunotherapy also offers opportunities to address distant disease and preclinical
data suggest immunotherapy in tandem with SBRT may be a rational way to induce an
“abscopal effect” although there are little clinical data as yet. By building on the proven
concept of conventional chemoradiation for patients with locally advanced NSCLC with
a subsequent radiation dose intensification to residual disease with SBRT concurrent
with immunotherapy, we hope address the issues of metastatic and local failures. This
“quadmodality” approach is still in its infancy but appears to be a safe and rational
approach to the improving the outcome of NSCLC therapy.
Keywords: stereotactic body radiation therapy, immunotherapy, radiation therapy, non-small cell lung cancer,
stage III

CHEMORADIATION IN STAGE III NON-SMALL
CELL LUNG CANCER (NSCLC)
One hundred years ago, lung cancer was a rare malignancy (1). Lung cancer today is the leading
cause of cancer death in the United States, with over 158,000 estimated deaths in 2016 (2). Forty
percent of these patients present with locally advanced disease (3). Approximately 80–90% of newly
diagnosed lung cancers are classified as NSCLC, primarily consisting of adenocarcinoma, squamous
cell carcinoma, or large cell carcinoma histologies. Historically, surgery has been the gold standard
for newly diagnosed NSCLC with early-stage resectable disease, resulting in 5-year overall survival
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rates (OS) of 50–70%. However, for patients with more locally
advanced NSCLC, 5-year OS after treatment with definitive
radiation therapy and concurrent chemotherapy remains modest, at approximately 15–20% (4). Prior to the advent of cytotoxic
chemotherapy, lung cancer at all stages was treated surgically or
by radiation alone (5, 6). TNM staging was introduced in 1974
and it helped shape the way lung cancer was managed. Stage III
lung cancer, though heterogeneous in its classification, includes
non-metastatic but locally advanced disease with involvement
of N1–N3 nodal stations and/or T3 and T4 primaries. Presently,
stage III lung cancer is managed with a combination of chemotherapy, radiation therapy, and sometimes surgery but the two
major challenges in improving outcomes of the treatment of this
disease remain local control and metastatic spread.

compared 60 versus 74 Gy both combined with weekly carboplatin
and paclitaxel. In this four-arm study, a second randomization of
cetuximab versus observation was also studied. Unfortunately an
interim analysis showed that the 74 Gy arm had increased risk of
death, with a median survival of 20 months for patients receiving
74 Gy versus 29 months for patients receiving 60 Gy, leading
to early termination of the study (10). There was no benefit to
local control. Of note, the 60 Gy arm had the highest median
survival demonstrated within a phase III trial for this patient
population. On multivariate analysis, increased dose to the heart,
represented as heart V5 and V30 (the percent volume receiving
≥5 and ≥30 Gy, respectively), maximum esophagitis grade, planning target volume, and radiation dose (74 Gy) were all shown
to negatively impact overall survival. There were no statistically
significant differences in ≥grade 3 toxic effects between the
groups; however, heart-specific toxicities were not assessed in this
trial. Ultimately this underlines the difficulty of dose escalation
with conventional radiation therapy fractionation techniques in
the general population of patients with stage III NSCLC, opening the door for new strategies to improve outcomes for locally
advanced disease. Often the argument is put forth that surgery is
the ultimate form of local control and indeed 5-year local control
rates for locally advanced NSCLC after CRT have been reported
as low as 15%, but at least some of this is possibly biased by the
selection of more resectable patients receiving surgery (11).
Improving local control of the primary lesion in NSCLC does
influence overall survival, as demonstrated by a meta-analysis of
concurrent CRT versus sequential chemotherapy and radiation
(12). Thus, if radiation techniques could be optimized and local
control improved, one could expect to see improvement in longterm patient survival.

CHEMORADIOTHERAPY (CRT)
DOSE ISSUES
Multiple studies have examined the issue of the optimal dose of
radiotherapy in NSCLC but are complicated by the heterogeneity
of the disease itself in terms of size and location of the primary
tumor, number and size of involved lymph nodes, and the patient’s
comorbidities, all of which limit the treatment tolerability and
risks. Delivery of tumoricidal doses to the primary tumor and
involved lymph nodes is balanced by treatment-related toxicities,
namely esophagitis, pneumonitis, and cardiac injury.
An early dose-finding study by the Radiation Therapy
Oncology Group (RTOG) 7301 study was conducted from 1973
to 1978 and studied four different doses and schedules: 40 Gy
split course, 40 Gy continuously, 50 Gy, and 60 Gy. All doses were
given in 2 Gy fractions. The optimal dose was determined to be
60 Gy (7).
Further improvements in survival were sought by the incorporation of chemotherapy. The Cancer and Leukemia Group B
8433 study solidified chemotherapy’s importance in the treatment of locally advanced lung cancer. In this phase III study,
155 patients with stage III NSCLC were randomized to receive
60 Gy in 30 fractions or induction chemotherapy consisting
of two cycles of cisplatin and vinblastine followed by 60 Gy
in 30 fractions. Both median OS (13.8 versus 9.7 months) and
3-year OS were improved in the CRT arm (23 versus 11%) (8).
Likewise, a European Organisation for Research and Treatment
of Cancer study showed a benefit to concurrent CRT by randomizing patients to split-course radiotherapy alone to a dose of
55 Gy, split-course radiotherapy plus low-dose daily cisplatin,
and split-course radiotherapy plus higher dose weekly cisplatin.
The most salient differences were seen between concurrent daily
CRT and radiation alone with the 3-year OS for CRT being 16
versus 2% for radiotherapy alone. This difference was thought
to be due to an improvement in local control, as the 2-year
local control in the daily CRT arm was 31 versus 19% in the
radiotherapy alone arm (9).
Only one phase III trial has compared the traditional standard
of 60 Gy to a modestly escalated dose regimen of 74 Gy. Based
on the results of RTOG 0117 suggesting that 74 Gy represented a
maximum tolerated dose of CRT for most patients, RTOG 0617
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INDIVIDUALIZED CRT
Since most dose-escalation studies have produced problematic
results in relatively unselected patients, can escalated radiation
doses safely be delivered to patients by adaptive radiotherapy
either during or after conventional radiotherapy? Additionally,
in an era of intense research into molecular markers and innovative systemic therapies, how can combination strategies best be
utilized to improve both local control and risk of metastasis?
Radiation Therapy Oncology Group 9311 was an early
multi-center dose-escalation trial of 179 patients which used
radiotherapy alone (13). The treatment was individualized based
on the volume of lung receiving 20 Gy or more (V20). Those with
a V20 less than 25% were dose-escalated to 90.3 Gy. Those with
a V20 of 25–36% were dose-escalated to 83.8 Gy. Both schemes
were performed at 2.15 Gy per fraction. Two treatment-related
deaths occurred in the 90.3 arm and this dose was labeled as
too toxic. Elective nodal coverage was not allowed, but still the
isolated nodal failure rate was less than 10%. For the group with a
V20 less than 25%, 83.8 Gy was found to be safe and for the group
with a V20 of 25–36% 77.4 Gy was found to be safe.
More recently Kong et al. reported results of a phase II study
of mid-treatment positron emission tomography-computed
tomography (PET/CT) adapted radiotherapy with concurrent chemotherapy (14). Briefly, in this study, 43 patients with

2

September 2017 | Volume 7 | Article 197

Kumar et al.

Emerging Therapies in Lung Cancer

unresectable stage II–III NSCLC received radiotherapy with
doses individualized for an allowable mean lung boost dose of
up to 20 Gy which would produce a risk of pneumonitis up to
17.5%. Radiation was delivered in 30 fractions with all patients
receiving 2.1–2.85 Gy/fraction for the initial dose up to approximately 50 Gy EQD2 with the adaptive phase of the treatment of
2.85–5.0 Gy/fraction for a total radiation dose of up to 86 Gy in
an attempt to deliver >100 Gy BED10. Weekly carboplatin and
paclitaxel were given concurrently. After a median follow-up of
47 months, the 2-year infield and overall local regional tumor
controls were 82 and 62%, respectively; and median OS was
25%. Overall these results are consistent with most other stage
III studies. This promising strategy of mid-treatment PET with
dose escalation is currently being evaluated in the RTOG 1106
randomized trial, which recently completed accrual. Though
local control has improved with these trials, metastatic disease
still remains an important site of failure.
Stereotactic body radiation therapy (SBRT) has changed the
standard of care for early-stage lung cancer, and data are emerging showing applicability to the stage III NSCLC population. The
evidence for a role of SBRT in the stage III lung cancer population
is summarized within this review.

control and survival for tumors less than 100 cc (20). Using 2 Gy
fractions, a dose of 70 Gy has a BED of 84 Gy.
Based on the success of Gamma Knife treatment of brain
lesions, extremely hypofractionated extracranial stereotactic
radiotherapy programs began in the 1990s and are commonly
known as SBRT or stereotactic ablative radiation therapy. SBRT
treatments, because of the high dose per fraction, are able to
achieve a much higher BED to localized volumes than conventional radiation delivered at 2 Gy/fraction. Multiple studies have
demonstrated that a higher BED is correlated with improved local
control and survival (21–24). Onishi et al. have shown that in
early-stage lung cancer, superior local control and survival are
achieved with treatment regimens that reach a BED of 100 Gy
or greater (21). Specifically in lung cancer, SBRT delivers a high
dose per fraction, with robust immobilization that minimizes
intra-fraction motion and tumor-related internal motion, allowing for overall reduction in size of treatment volumes and overall
treatment time.
In the seminal clinical reports by Blomgren and Lax, the
philosophy and treatment parameters for the hypofractionated
highly conformal treatment of localized disease that we use today
were elucidated (25). In an ad hoc manner, they treated a number
of different sites of localized disease most notably early-stage lung
cancers settling on a dose of 60 Gy in three fractions of 20 Gy each
with excellent local control and minimal toxicity. Their studies
defined the parameters required for safe and precise delivery that
we utilize in SBRT delivery today. Presciently, they speculated that
“this new technique may also be used for delivering boost doses
with a high precision after conventional radiation therapy” (26).

BIOLOGICALLY EFFECTIVE DOSE (BED)
AND SBRT
The success of SBRT treatments in early-stage NSCLC likely
reflects the radiobiologic properties of high radiation doses.
Higher radiation doses result in exponential increases in cell kill,
and may also have an ablative effect on tumor vascularity and
stroma (15, 16). A method of dose modeling based on the linear
quadratic model of cell killing, referred to as the BED, takes into
account the radiation dose per fraction and the inherent radiation
response of a particular tissue (17). As derived from linear quadratic curves, mathematically two different dose and fractionation
schemes can be compared theoretically for tumor control probability. An important assumption of this model is referred to as the
α/β ratio, simplistically thought of as the ratio of cell killing based
on single hit and multi-hit kinetics that leads to local control of
a cancer mass (primarily from cell culture experiments, animal
data and clinical observation). Nevertheless, tumor control probabilities are more complicated than a simple mathematical statement since tissues are complicated structures with underlying
vasculature, stroma, and tumor cells, all of which interact (18).
Many of the α/β assumptions are, therefore, also based on long
clinical observation of tumor control and normal tissue toxicities. The BED equation can be expressed as BED = nd(1 + d/α/β)
where n = the number of fractions, d = the dose/fraction, and
α/β = alpha-beta ratio. Often early-reacting tissues/tumor cells
are considered to have an α/β of approximately 10 whereas late
reacting tissues are assigned an α/β of approximately 3. Based
on these assumptions, Martel et al. constructed a mathematical
model which predicted that in NSCLC a dose 84 Gy must be
achieved for a local progression-free survival (PFS) of greater
than 30 months (19). A retrospective study found that the doses
of at least 70 Gy at 1.8–2 Gy per fraction provided better local
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SBRT CLINICAL TRIALS IN
EARLY-STAGE LUNG CANCER
In an effort to better define SBRT doses for localized disease,
Timmerman et al. performed a phase I-II dose-escalation
study for SBRT to the primary tumor in patients with stage I
NSCLC using the concept derived from Swedish studies (27).
Inhomogeneity corrections to correct for lung density were not
performed. Separate cohorts of patients were followed with the
dose-escalation ending at 60 Gy in 20 Gy fractions with no doselimiting toxicity. Termination of the dose escalation for these
smaller tumors was based on modeling of cell kill. For larger
tumors (up to 7.0 cm) a dose-limiting toxicity (pneumonitis)
was reached at 72 Gy in 24 Gy fractions. This experience laid
the groundwork for further national clinical trials evaluating
SBRT as a therapy for medically inoperable early-stage NSCLC,
and ultimately changed the standard of care for these patients.
Currently, SBRT is defined as 1–5 treatments of high-dose radiation delivered to tumors, typically measuring up to 7 cm, with
registration of the patient’s anatomy to a 3-D coordinate system
either physical or within the planning system. SBRT is considered
an ablative treatment intended to disrupt cellular clonogenicity,
and lead to cell death. Robust immobilization, control of internal
organ and tumor motion, sharp dose gradients, and high dose
per fraction (≥600 cGy) for five or fewer fractions have been
considered to define SBRT.
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The first North American prospective cooperative group clinical trial evaluating SBRT, RTOG 0236 began accrual in 2004 and
only allowed “peripherally located” tumors as defined by being
outside 2 cm of the proximal bronchial tree or mediastinum
(commonly referred to as the “no fly” zone). This study accrued
59 patients, treated with 18 Gy × 3 (total 54 Gy with heterogeneity
corrections) to the primary tumor, and demonstrated 3-year local
control (involved tumor and primary lobe) of 91% for patients
with T1-2, N0 medically inoperable lung cancer (28). Three-year
local–regional control was 87%, and distant failure rate was 22%.
Overall survival was 56%. Results from longer follow-up have
shown higher rates of local failure, primarily due to intralobar
recurrences, with 5-year local recurrence rates of 20% (29).
Importantly, these clinical outcomes are far better than historical studies treating medically inoperable early-stage lung cancer
with conventionally fractionated radiation (2 Gy/fraction), with
dismal local control of the primary tumor of 50% or less (30).
Grade 3 and higher adverse events occurred in approximately
15% of patients enrolled in RTOG 0236.
For centrally located tumors, RTOG 0813 was a phase I-II
study for T1-2, N0 medically inoperable lung cancer 5 cm or less
in size, centrally located within or touching the 2 cm bronchial
tree “no fly” zone. The primary endpoint was to establish the optimal SBRT dose for centrally located tumors. With dose cohorts of
10 Gy × 5, 10.5 Gy × 5, 11 Gy × 5, 11.5 Gy × 5, and 12 Gy × 5, it
was found that the highest dose cohort had a 7% probability of a
dose-limiting toxicity (31). RTOG 0915 was a randomized phase
II study designed to test 34 Gy × 1 versus 12 Gy × 4 for noncentrally located tumors, with a primary endpoint of determination of the regimen with the lowest rates of protocol specified
adverse events at 1 year. One year adverse events were 10% for
the 34 Gy arm, and 13% for the 48 Gy arm (32).
It thus appears that there are multiple hypofractionated
schemes that are acceptable using SBRT techniques to achieve
high degrees of local control but they all have one thing in common: BED > 100.

Nonetheless, a large body of literature is accumulating confirming that SBRT treatment is well tolerated and safe in patients
who are medically inoperable with early-stage lung cancer and
produces excellent results. The question of applying SBRT to a
stage III population with centrally located mediastinal lymph
nodes as well as primary tumors remains pertinent. The studies
summarized below describe the experience of SBRT in the locally
advanced, stage III patient population.

DOSE-ESCALATED HYPOFRACTIONATED
RADIATION (SBRT) IN STAGE III NSCLC
Investigators at the University of Kentucky completed a prospective study evaluating the feasibility of conventional CRT followed
by a SBRT boost to the primary tumor as a method to dose escalate
in patients with residual disease following CRT (35). In this study,
patients with stage IIIA and IIIB NSCLC received CRT (median
dose of 59.4 Gy) followed by a whole body fluorodeoxyglucosepositron emission tomography (FDG-PET) scan 1 month after
treatment. Eighty-nine percent of patients received concurrent,
platinum-based chemotherapy during CRT. Patients were
eligible for SBRT if they had evidence of residual disease at the
primary tumor location that was ≤5 cm in greatest dimension.
Patients with progressive metastatic disease, contralateral lung
disease or residual disease in the hilum or mediastinum were
not eligible (defined as SUV ≥ 2). SBRT doses were 6.5 × 3 for
centrally located primary tumors, and 10 Gy × 2 for non-central
tumors. With these dose schemas, the cumulative BED10 to the
primary tumor was 110 Gy for non-central tumors and 102 Gy for
centrally located tumors. Sixty-two patients were screened, and
37 patients were ultimately eligible and enrolled. Approximately
31% of patients screened had new metastatic disease and an
additional 31% had persistent nodal disease on post-treatment
FDG-PET. The primary endpoint of this study was to assess
the proportion of patients who developed ≥grade 3 radiation
pneumonitis, according to the RTOG acute and late radiation
morbidity scoring criteria. Overall, 11.4% of patients experienced
radiation pneumonitis consistent with rates found in most studies
of conventional CRT suggesting no increase risk with the SBRT
boost. Two patients developed fatal pulmonary hemorrhage felt
to be possibly related to treatment but careful analysis showed
that these cases were more likely to have been related to squamous
cell cavitary recurrences involving the hilum (36). Statistically
there were no differences dosimetrically between patients who
developed a fatal hemorrhage from those who did not. Local
recurrence remained the most significant predictor. The central
structures including the bronchial walls, pulmonary arteries, and
aorta were contoured and the individual doses delivered to these
structures were compared as well as the location of the PTV to the
hilum. This small series of patients suggested that it is prudent to
restrict the maximum radiation dose to the pulmonary artery to
less than 185 Gy cumulative BED3, and to less than 120 Gy BED3
for the 5 cc volume; as well as limiting the maximum dose to the
bronchial wall to less than 175 Gy BED3. The equivalent dose on
a per fraction basis would be equivalent to limiting each of these
structures to less than 700 cGy per fraction times 3, or 900 cGy

SBRT TOXICITY
Though grade 3–5 toxicities with SBRT are overall low, Timmerman
et al. retrospectively found in the initial single institution phase II
study that 20–22 Gy × 3 was overly toxic for tumor in a central
location, defined as within 2 cm from the proximal bronchial tree.
In this phase II study, 2-year freedom from severe toxicity was
83% in patients with peripheral tumors and 54% for patients with
central tumors (33). A separate single institution study recently
showed a 3.7% fatal toxicity rate for SBRT with central tumors,
with tumors abutting the proximal bronchial tree having significantly more grade 3+ adverse events (31 versus 7%) (34).
This suggests that tumor location with regards to the potential
for late toxicity attributable to SBRT may be important as described
above, but the RTOG 0813 SBRT dose-escalation study shows
that central tumors may be safely treated to significant SBRT
doses (31). As data and experience accumulates, dose-limiting
organs within the hilum and mediastinum are becoming better
defined and with care, SBRT can be utilized to treat “central”
tumors safely.
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per fraction times 2 for the boost, assuming that the patient
has previously received between 60 and 66 Gy using standard
fractionation. The most recently reported long-term follow-up of
this study shows a crude local control rate of 78%. Median overall
survival was 25 months. There were no significant late toxicities
seen within the study population (37).
Second, a recent phase I study by Higgins et al. (in press) evaluated the optimal SBRT dose after 44 Gy CRT. Inclusion criteria
included stage IIIA or IIIB NSCLC, with a primary tumor of 8 cm
or less and no N1 or N2 nodal station >5 cm in maximum dimension. This multi-institution phase I study enrolled 15 patients,
and dose-escalated a SBRT boost according to the following dose
cohorts: 9 Gy × 2, 10 Gy × 2, 6 Gy × 5, 7 Gy × 5. Patients received
44 Gy with weekly carboplatin and paclitaxel, and then underwent
a second computed tomography (CT) simulation after 40 Gy was
delivered. The SBRT boost was then planned to encompass all
residual primary and nodal disease as seen on the planning CT
simulation. This volume was then dose-escalated according to the
dose assignment of the patient. The maximum tolerated dose was
determined to be 6 Gy × 5. There was one treatment-related grade
5 toxicity at this dose level, and 10 Gy × 2 is felt to be the most
optimal SBRT boost dose, as no grade 3 or higher toxicities were
seen in patients treated within the dose cohort. For all patients,
actuarial local regional control at 3 years was 59%, and 3-year
overall survival was 39% (38).
In an additional phase I study by Hepel et al., 12 patients with
stage III NSCLC who had a primary tumor volume <120 cc
(approximately 6.0 cm) and nodal disease volumes <60 cc
received CRT to a dose of 50.4 Gy in 28 fractions (39). The study
used a dose-escalation design to identify the maximum tolerated
dose. SBRT dose was escalated from 16 Gy in two fractions to
28 Gy in two fractions in 2 Gy/fraction increments, resulting
in four potential dose cohorts. The endpoint was dose-limiting
toxicity occurring within 4 weeks of SBRT. A standard phase I
cohort design was used. SBRT cohort doses started at 800 cGy × 2
fractions and escalated by 200 cGy/fraction to a final dose of
1,400 cGy × 2 for a total SBRT boost of 28 Gy. No early grade 3–5
toxicities were noted and at a median follow-up of 16 months,
1 year local–regional control was 78% with 100% at ≥24 Gy.
Overall survival at one year was 67%. One late fatal pulmonary
hemorrhage was noted and it was determined that the patient’s
4 cc proximal bronchial-vascular tree dose was substantially
higher than all patients reported at 30.2 Gy for the SBRT boost
and 73.5 Gy for the total treatment. A total BED computation was
not available to assess all patient doses.
It is clear from these studies and RTOG 0813, contouring of at
risk structures and applied dose constraints (see above estimates)
particularly for the pulmonary vasculature need to be respected
in the treatment plan.

tightly controlled to prevent rampant autoimmunity. Multiple
mechanisms to regulate immune responses have been shown
to exist including innate tolerance to self-antigens, a network of
both B and T suppressor cells and more recently elucidation of
molecular regulatory mechanisms including checkpoint inhibitors. Immune checkpoint inhibitors have shown some promise in
modulating the tumor microenvironment so that evasion of the
immune system is more difficult.
Surveillance and destruction of tumor cells is postulated to
be effected by the immune system and the vanguard of early
tumor control may be the natural killer cell although its full
role is yet to be elucidated. Once a tumor is established, control
may be mediated by activated T-lymphocytes including CD4+
and CD8+ cells. The CTLA-4 and programmed death ligand 1
(PD-1) pathways are two T-cell inhibitory pathways that may
modulate immune responses to lung antigens in the presence of
an increasing burden of malignant cells possibly in an effort to
prevent damage to host normal tissues. Inadvertently this may
result in suppression of the immune system favoring tumor cell
survival and growth. A CTLA-4 monoclonal antibody which is
currently in use is ipilimumab, currently indicated in the treatment of melanoma. The PD-1 receptor ligands include PD-L1 and
PD-L2. Nivolumab and pembrolizumab are two PD-1 inhibitors
which have been FDA approved for clinical use in lung cancer.
Several seminal trials suggested the utility of blocking the
PD inhibitory pathway by monoclonal antibodies to harness the
immune system in control of NSCLC. The Checkmate 057 phase
III clinical trial randomized 582 patients with non-squamous
metastatic NSCLC who had progressed during or after platinumbased chemotherapy to salvage docetaxel chemotherapy or
nivolumab. Median OS was longer in the nivolumab group
(12.2 versus 9.4 months). Patients with even <10%, but greater
than 1% PD-L1 expression showed a benefit with nivolumab
over docetaxel (40). A second study, Checkmate 017, studied 272
patients with metastatic squamous cell NSCLC who progressed
through platinum-based first-line chemotherapy. Those who
received nivolumab had a median OS of 9.2 months versus those
who received docetaxel, with a median OS of only 6.0 months
(41). The use of nivolumab as a first-line agent was explored in
the phase III Checkmate 026 trial in which 541 patients with
previously untreated metastatic NSCLC with at least 1% PD-L1
expression were randomized to nivolumab or standard-of-care
platinum doublet chemotherapy. Both PFS and OS were not
significantly different between the two arms (42).
The KEYNOTE-010 trial enrolled over 1,000 patients with
previously treated advanced NSCLC with at least 1% PD-L1
expression. They were randomized to two different doses of
pembrolizumab or docetaxel. Median OS was 10.4 months
with 2 mg/kg of pembrolizumab, 12.7 months with 10 mg/kg
of pembrolizumab, and 8.5 months with docetaxel, which was
statistically significant. An even greater survival benefit was
seen in those with >50% tumor PD-L1 expression: 14.9 months
with 2 mg/kg of pembrolizumab, 17.3 months with 10 mg/kg
of pembrolizumab, and 8.2 months with docetaxel, which was
also statistically significant (43). As a first-line therapy, the phase
III KEYNOTE 024 trial explored the use of pembrolizumab
in advanced NSCLC with at least 50% PD-L1 staining versus

IMMUNOTHERAPY IN NSCLC
The use of immunotherapy in NSCLC is rapidly burgeoning.
Early vaccine trials and trials with interferon therapy for those
who were suffering from NSCLC have been largely negative
and led to the hypothesis that NSCLC was believed to be largely
non-immunogenic. Clearly, the immune response must be
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cytotoxic chemotherapy, which was up to the discretion of the
treating physician. Only 30% of the patients had the required 50%
or greater PD-L1 staining tumors. In those patients, pembrolizumab was seen to significantly increase the 6-month OS (80.2
versus 72.4%) (44).
PD-L1 reactive monoclonal antibodies are currently being
explored in NSCLC. Atezolizumab is one such IgG1 agonist to
PD-L1. In the OAK trial, 1,225 patients with advanced NSCLC
were randomized to salvage chemotherapy with docetaxel or
atezolizumab. Greater OS was seen with atezolizumab regardless
of PD-L1 expression (13.8 versus 9.6 months) (45).
To date, there are only limited data from phase III trials
regarding immunotherapy for stage III NSCLC. The phase III
START trial enrolled 1,514 patients with stage III NSCLC who
had received CRT and had not progressed within 1–3 months.
Patients were randomized to either placebo or tecemotide, an antiMUC-1 immunotherapy designed to stimulate a T-cell response
against the MUC-1 protein. There was no OS difference between
the placebo group and the tecemotide group, except in a subgroup
receiving concurrent CRT. In this case, the tecemotide group did
have an improved OS (46), suggesting a possible synergistic interaction between the radiation and the drug. Belagenpumatucel-L
is a tumor vaccine of four allogeneic NSCLC cell lines. In a
phase III trial, 270 stage III or IV patients who were treated with
platinum-based chemotherapy and who had not progressed were
randomized to receive placebo or belagenpumatucel-L. There
were no differences in OS or PFS between the two arms (47). A
killed Mycobacterium vaccae named SRL172 was the subject of a
phase III clinical trial published in 2004. A total of 419 patients
were treated with 6 cycles of mitomycin, vinblastine and cisplatin or carboplatin with or without monthly administration of
SRL172. There were no differences in overall survival, but patients
in the SRL172 arm reported better quality of life (48). A metaanalysis of 20 trials by Zhou et al. found an OS benefit to immune
checkpoint inhibitors and therapeutic vaccine (49).

markers, adhesion molecules, cytokines, and many others (53).
Single doses of 15–25 Gy induced strong T-cell responses, but
these immune responses were dampened by the use of fractionated radiation or chemotherapy (54). Unfortunately, since
lymphocytes are so radiosensitive, only a low integral dose is
needed to kill any surrounding tumor lymphocytes. There is some
evidence that ablative radiation fraction sizes (at least 6 Gy) or
high linear energy transfer radiation causes increased release of
immunogenic antigens. Mouse studies have shown evidence of
the abscopal effect after use of large fractions (55, 56). A paper by
Lugade et al. looked at 15 Gy in a single fraction versus 15 Gy in
5 fractions of 3 Gy in in a mouse melanoma model. They found
that both fraction sizes lead to tumor-infiltrating lymphocytes
that were capable of lysing tumor cell targets, but that the larger
fraction size produced better results (57). A strong antitumor
immunogenic response was observed in mouse models after
being treated with a carbon ion beam. This resulted in fewer
contralateral squamous cell tumors, which is thought to be due
to an immune-mediated abscopal effect (58). Strictly defined,
the abscopal effect is the resulting shrinkage or disappearance
of metastatic deposits following treatment of the primary tumor
mass. Clinically the abscopal effect is rarely seen, with fewer than
50 documented cases in the literature (59). Barid et al. propose
that this is because while radiotherapy provides available antigen,
it does not provide the necessary co-stimulation of T cells or
cytokine release (60). Thus, this presents an opportunity for the
combined use of radiotherapy and immunotherapy.
Both laboratory and clinical evidence exist regarding the
advantage of combined radiotherapy and immunotherapy.
In a murine model of metastasis, squamous cell carcinoma cell
lines were inoculated into the mouse thigh typically requiring
≥106 tumor cells to ensure tumor growth. Most of these cells
die and release tumor lysis products which may bias treatment
results. Mice were treated with a single 6 Gy dose of carbon
ions and 36 h later treated with α-galactosylceramide-pulsed
dendritic cells. Compared to the untreated control mice, these
mice developed significantly fewer pulmonary metastases (61).
Intravenous administration of isolated dendritic cells with either
carbon beam therapy or photon beam therapy was compared in a
murine model. Both types of irradiation produced an antimetastatic effect, but carbon ions did so at a lower BED (62). Sharabi
et al. examined the effect of SBRT in murine melanoma or breast
cancer and found that the effect of radiation was enhanced in the
presence of a PD-1 inhibitor or regulatory T-cell depletion (63).
Some studies suggest that an immune-mediated abscopal effect
is increased with fractionated radiotherapy using large fractions
in addition to a CTLA-4 inhibitor as opposed to single-dose
radiotherapy (64). Indeed, further mouse studies confirmed that
fractionation using “medium-sized doses” (7.5 Gy per fraction)
provided both low numbers of regulatory T-cells and the best
control of the tumor (65).
Clinical studies also show encouraging results of the use of
combined radiation and immunotherapy. Abscopal effects in
humans after SBRT with or without immunotherapy have been
reported in both renal cell carcinoma and melanoma (66–68).
The KEYNOTE-001 study predated the KEYNOTE-010 study.
KEYNOTE-001 was a phase I clinical trial which enrolled 495

RATIONALE FOR THE USE OF
IMMUNOTHERAPY WITH RADIOTHERAPY
Immunogenic cell death is a postulated mechanism of radiation
injury. Classically it is thought that the immune system must
recognize either foreign (e.g., viruses) or mutated antigens on
tumor cells to initiate an immunostimulatory response. Thus
far, no simple antigen has been identified since in many ways,
cancer cells are “self.” Roszik et al. found a significant relationship between the predicted tumor mutation load and clinical
benefit from ipilimumab, T-cell therapy, and pembrolizumab
suggesting mutated proteins or DNA-protein complexes may be
immunostimulatory (50). Unlike conventional apoptosis, when
due to an immunogenic cell death apoptosis causes a release of
molecules which may lead to an inflammatory or augmented
immune response (51, 52). Damaged cells produce damage-associated molecular patterns which lead to uptake and subsequent
presentation of tumor antigen by dendritic cells. Radiation has
been shown to release or upregulate immune and tumor-related
molecules such as major histocompatibility complex, tumor
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patients with advanced NSCLC. They were treated with pembrolizumab at doses of 10 mg/kg every 3 weeks or 10 mg/kg every
2 weeks. The objective response rate was found to be 19.4% and OS
was 12 months. In patients with at least 50% expression of PD-L1
median overall survival was not reached. It was deemed to have
an acceptable side effect profile and the most common side effects
included fatigue, itching, and decreased appetite (69). An analysis
of the trial was done and showed that in 97 patients who had
prior radiation PFS and overall survival were significantly longer,
especially for those who received extracranial radiotherapy (70).
In the PACIFIC study, a phase III study for stage III unresectable
lung cancer, patients in the experimental arm received chemoradiation followed by durvalumab for 12 months. In a preliminary
report, Astra Zeneca suggests an improvement in PFS in the
immunotherapy arm was seen, however, these data have yet to be
presented (71). Currently, there are several ongoing clinical trials
investigating the use of immunotherapy with radiotherapy. These
trials include agents such as cancer vaccines, CTLA-4 inhibitors,
PD-1 inhibitors, and PD-L1 inhibitors (Table 1). This table was
generated by searching the ClinicalTrials.gov database with
search terms such as “radiation,” “chemoradiation,” “thoracic RT,”
and several variations. The results were then manually filtered for
the inclusion of Immunotherapy.

We need more innovative approaches to management of this
disease. Evidence is accumulating that dose escalation of radiotherapy improves local control of much of the microscopic and
gross disease in the chest. Since dose escalation by conventional
radiation delivery has been compromised by toxicity, the careful
delivery of hypofractionated radiation therapy (SBRT) to the
sites of gross disease should improve local control by ablating
any residual viable cancer cells. The initial studies of SBRT boost
while small, show this approach is safe and feasible, but the
impact of this approach on survival in the management of stage
II-III awaits larger studies.
The sequencing and combination of this “quadmodality” approach is still being explored. In the Phase I/II studies
described above, concurrent chemoradiation to a dose of
44–60 Gy was used which was followed by an SBRT boost. The
trials showed favorable toxicity profiles using this approach.
Fractionated chemoradiation promotes immunotolerence
through the killing of lymphocytes by the chemotherapy and
radiation therapy, but SBRT has been shown to induce strong
T-cell responses. Thus ideally the patient would undergo
concurrent chemoradiation to a dose of 44–60 Gy, have an
approximately 2-week break to allow for SBRT treatment planning and recovering from leukopenia, then get an SBRT boost.
In order to capitalize on the immunostimulatory effects of the
SBRT, the immunotherapy should be administered soon (within
1 week) of the SBRT boost. Cranial stereotactic radiosurgery
with concurrent immunotherapy appears to be well tolerated,
but data on lung SBRT and concurrent immunotherapy is still
developing. Theoretically, there could be an increased risk for
toxicity, especially induced auto-immune effects, due to this
quadmodality approach. Indeed, the SBRT boost followed by
immunotherapy may prime the immune system to attack not
only tumor cells but normal tissue as well.
From a metastatic viewpoint, immunotherapy is an exciting
option that is still in its infancy. There are adequate early and
non-clinical data suggesting that hypofractionated radiation and
immunomodulation may be synergistic. Thus, a more cogent
approach to trials addressing both local control and metastatic

SUMMARY
Treatment of locally advanced lung cancer has not made great
strides since the 1990s when cytotoxic chemotherapy was combined
with radiation. The two major stumbling blocks to improvements
in survival of these patients are local control and distant metastasis.
It is clear that SBRT for stage I NSCLC is one of the most important
treatment advancements in decades with excellent outcomes of
high local tumor control and survival with low toxicity.
Cytotoxic chemotherapy remains an important modality in
more advanced disease but has reached a point where major
improvements are unlikely and despite systemic therapy, metastatic disease is a prominent cause of death in locally advanced
NSCLC patients.

TABLE 1 | Active clinical trials involving the use of both radiotherapy and immunotherapy such as cancer vaccines, CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1
inhibitors in Stage III non-small cell lung cancer (NSCLC).
NCT Number

Title

Recruitment

Study results

Phase

Enrollment

NCT02987998

Neoadjuvant chemoradiation plus pembrolizumab followed by
consolidation pembrolizumab in NSCLC

Recruiting

No results available

Phase 1

20

NCT02662634

A safety and feasibility study of AGS-003-LNG for the treatment of stage 3 NSCLC

Recruiting

No results available

Phase 2

20

NCT02434081

NIvolumab consolidation with standard first-line chemotherapy and radiotherapy
in locally advanced stage IIIA/B non-small cell lung carcinoma

Recruiting

No results available

Phase 2

43

NCT02318771

Radiation therapy and MK-3475 for patients with recurrent/metastatic head
and neck cancer, renal cell cancer, melanoma, and lung cancer

Recruiting

No results available

Phase 1

40

NCT02621398

Pembrolizumab, paclitaxel, carboplatin, and radiation therapy in treating
patients with stage II-IIIB NSCLC

Recruiting

No results available

Phase 1

30

NCT02768558

Cisplatin and etoposide plus radiation followed By nivolumab/placebo for
locally advanced NSCLC

Recruiting

No results available

Phase 3

660

NCT02125461

A global study to assess the effects of MEDI4736 following concurrent
chemoradiation in patients with stage III unresectable NSCLC (PACIFIC)

Ongoing, but
not recruiting

Active, not recruiting Phase 3

713
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disease may become “quadmodality” and include combining
chemotherapy, conventionally fractionated radiation therapy,
immunotherapy and SBRT dose intensification to ablate the
residual primary tumor mass. Given the continued devastating
effect of lung cancer on the world, such trials need to be developed promptly.
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